Additionally, specific gene mutations such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and cytogenetic abnormalities such as t(11;14) are identified in myeloma cells, where BRAF inhibitors and venetoclax may be effective [109,110,111,112,113]. This evidence concerns the gene BRAF and plasma cell myeloma.